Superior efficacy of oral ganciclovir over oral acyclovir for cytomegalovirus prophylaxis in kidney-pancreas and pancreas alone recipients

Transplantation Proceedings

Volumn 30, Issue 4, 1998, Pages 1546-1548

  Somerville, T ^a,b   Hurst, G ^a   Alloway, R ^a   Gaber, A ^a   Shokouh Amiri, M H ^a   Stratta, R ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VT Bowld Hospital Pharmacy Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR;

ADULT; BIOAVAILABILITY; CLINICAL ARTICLE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS; DRUG EFFICACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; ORAL DRUG ADMINISTRATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; PROPHYLAXIS; RECIPIENT; VIRUS INFECTION;

ACYCLOVIR; ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; COSTS AND COST ANALYSIS; CROSS-SECTIONAL STUDIES; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; PANCREAS TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TENNESSEE; TIME FACTORS;

EID: 0031804671     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(98)00352-2     Document Type: Conference Paper

References (7)

1. Elmer DS, Hathaway DK, Gruessner A, et al: Acta Diabeologia 34:127, 1997
2. Patel R, Snydman DR, Rubin RH, et al: Transplantation 61:1279, 1996
3. Pirsch JD, Andrews C, Hricik DE, et al: Am J Kidney Dis 27:444, 1996
4. Zaia JA: Adv Exp Med Biol 394:117, 1996
5. Anderson RD, Griffy KG, Jung D, et al: Clin Ther 17:425, 1995
6. Rubin RH: JAMA 261:3607, 1989
7. Tolkoff-Rubin NE, Rubin RH: Transplant Proc 26(suppl 1):16, 1994